CV-03 / CUREVERSE - LARVOL DELTA

Discovery of highly selective, orally available small-molecule DDR1 inhibitors that reprogram the collagen-DDR1 tumor microenvironment (AACR 2026) - "Our inhibitors act as Type II, DFG-out state-specific binders, occupying a previously unexploited pocket in DDR1. This poster describes the discovery, structural validation, and optimization of a novel, lead-stage selective DDR1 inhibitor."

Biomarker • Late-breaking abstract • Tumor microenvironment • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • DDR1